California Public Employees Retirement System Has $31.35 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

California Public Employees Retirement System trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 225,173 shares of the life sciences company’s stock after selling 9,772 shares during the quarter. California Public Employees Retirement System’s holdings in Illumina were worth $31,353,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Illumina during the third quarter valued at about $30,000. VisionPoint Advisory Group LLC grew its holdings in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Illumina during the fourth quarter valued at about $37,000. Gradient Investments LLC grew its holdings in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after buying an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. grew its holdings in shares of Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after buying an additional 194 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 1.0 %

NASDAQ ILMN opened at $122.28 on Friday. The company’s 50 day moving average is $131.51 and its 200-day moving average is $127.31. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $213.91. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the firm posted $0.14 earnings per share. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.17% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Barclays raised their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. Finally, TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.